gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TCRTHealthcarePharmaceuticals

Alaunos Therapeutics, Inc. Common Stock (TCRT)

$1.80−3.23%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.80▼ 28.57% in range
Nov 4, 2025Low $0.74 · High $4.36Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Alaunos Therapeutics closed at $1.80 on Nov 4, down 3.23%, 58.7% below its 52-week closing high. Volume of 134.3K shares was 0.01× its 20-day average (below normal).

Split-adjusted performance: +142.4% over one month, -31.6% over six months, -33.6% over one year.

Short interest was 818.6K shares at the Oct 15 settlement, up 8308.0% from the prior report (30.4% of float, 1.0 days to cover).

Market cap$4.6M2.5M shares
Revenue · quarter$0.00—
Diluted EPS$-0.41—
P/E · TTM—P/S 1,524.3×
Net margin—
Dividend yieldNone
52-week range0.74 – 4.36−58.7% from high
Volume134.3K0.01× 20-day avg
Volatility · 60d273.2%Annualised
Short % of float30.4%1.0 days to cover
Net cash$124.0KCash $124.0K
Next earnings—Not scheduled
Split-adjusted performance
1W −15.5%1M +142.4%3M −9.5%6M −31.6%YTD −44.3%1Y −33.6%3Y −84.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum44
Revenue growth—
Net margin—
Value (low P/E)—
Size8

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short818.6K+8308.0% vs prior
Days to cover1.0Settled Oct 15
% of float30.4%
Short vol. 10d60.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TCRTAlaunos Therapeutics$1.80−3.23%−31.6%———$4.6M
XBIOXenetic Biosciences$2.01−3.37%−36.6%+12.0%−140.7%—$4.7MCompare
APUSApimeds Pharmaceuticals US$2.92−1.68%−85.0%———$4.4MCompare
DRMADermata Therapeutics$0.8548+0.72%−32.7%———$4.2MCompare
AZTRAzitra$0.8157−7.71%−66.7%———$4.9MCompare
SKYESkye Bioscience$1.14−6.56%−83.3%———$5.0MCompare
TRAWTraws Pharma$0.2686−11.06%−84.2%−100.0%——$4.1MCompare
IMNNImunon$0.9070+0.78%−66.5%———$5.1MCompare
ONCOOnconetix$0.6583+15.69%−85.4%−83.9%−16748.3%—$3.9MCompare

News about Alaunos Therapeutics

All news →

No recent articles focused on Alaunos Therapeutics.

Quick answers

What does Alaunos Therapeutics do?
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs.
What is TCRT's market cap?
$4.57M, based on the Nov 4 close of $1.80.
Does Alaunos Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TCRT is sold short?
818.6K shares, 30.4% of float, as of Oct 15, 2026.
What sector is TCRT in?
Healthcare, in the Pharmaceuticals industry.

About Alaunos Therapeutics

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

HQ: Fort Lauderdale, FL1 employeesListed Aug 24, 2005alaunos.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology